Cargando…
Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases
The prevalence of renal diseases is rising and reaching 5–15% of the adult population. Renal damage is associated with disturbances of body homeostasis and the loss of equilibrium between exogenous and endogenous elements including drugs and metabolites. Studies indicate that renal diseases are infl...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486071/ https://www.ncbi.nlm.nih.gov/pubmed/28604601 http://dx.doi.org/10.3390/ijms18061248 |
_version_ | 1783246194347081728 |
---|---|
author | Gluba-Brzózka, Anna Franczyk, Beata Olszewski, Robert Banach, Maciej Rysz, Jacek |
author_facet | Gluba-Brzózka, Anna Franczyk, Beata Olszewski, Robert Banach, Maciej Rysz, Jacek |
author_sort | Gluba-Brzózka, Anna |
collection | PubMed |
description | The prevalence of renal diseases is rising and reaching 5–15% of the adult population. Renal damage is associated with disturbances of body homeostasis and the loss of equilibrium between exogenous and endogenous elements including drugs and metabolites. Studies indicate that renal diseases are influenced not only by environmental but also by genetic factors. In some cases the disease is caused by mutation in a single gene and at that time severity depends on the presence of one or two mutated alleles. In other cases, renal disease is associated with the presence of alteration within a gene or genes, but environmental factors are also necessary for the development of disease. Therefore, it seems that the analysis of genetic aspects should be a natural component of clinical and experimental studies. The goal of personalized medicine is to determine the right drug, for the right patient, at the right time. Whole-genome examinations may help to change the approach to the disease and the patient resulting in the creation of “personalized medicine” with new diagnostic and treatment strategies designed on the basis of genetic background of each individual. The identification of high-risk patients in pharmacogenomics analyses will help to avoid many unwarranted side effects while optimizing treatment efficacy for individual patients. Personalized therapies for kidney diseases are still at the preliminary stage mainly due to high costs of such analyses and the complex nature of human genome. This review will focus on several areas of interest: renal disease pathogenesis, diagnosis, treatment, rate of progression and the prediction of prognosis. |
format | Online Article Text |
id | pubmed-5486071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54860712017-06-29 Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases Gluba-Brzózka, Anna Franczyk, Beata Olszewski, Robert Banach, Maciej Rysz, Jacek Int J Mol Sci Review The prevalence of renal diseases is rising and reaching 5–15% of the adult population. Renal damage is associated with disturbances of body homeostasis and the loss of equilibrium between exogenous and endogenous elements including drugs and metabolites. Studies indicate that renal diseases are influenced not only by environmental but also by genetic factors. In some cases the disease is caused by mutation in a single gene and at that time severity depends on the presence of one or two mutated alleles. In other cases, renal disease is associated with the presence of alteration within a gene or genes, but environmental factors are also necessary for the development of disease. Therefore, it seems that the analysis of genetic aspects should be a natural component of clinical and experimental studies. The goal of personalized medicine is to determine the right drug, for the right patient, at the right time. Whole-genome examinations may help to change the approach to the disease and the patient resulting in the creation of “personalized medicine” with new diagnostic and treatment strategies designed on the basis of genetic background of each individual. The identification of high-risk patients in pharmacogenomics analyses will help to avoid many unwarranted side effects while optimizing treatment efficacy for individual patients. Personalized therapies for kidney diseases are still at the preliminary stage mainly due to high costs of such analyses and the complex nature of human genome. This review will focus on several areas of interest: renal disease pathogenesis, diagnosis, treatment, rate of progression and the prediction of prognosis. MDPI 2017-06-10 /pmc/articles/PMC5486071/ /pubmed/28604601 http://dx.doi.org/10.3390/ijms18061248 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gluba-Brzózka, Anna Franczyk, Beata Olszewski, Robert Banach, Maciej Rysz, Jacek Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases |
title | Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases |
title_full | Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases |
title_fullStr | Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases |
title_full_unstemmed | Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases |
title_short | Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases |
title_sort | personalized medicine: new perspectives for the diagnosis and the treatment of renal diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486071/ https://www.ncbi.nlm.nih.gov/pubmed/28604601 http://dx.doi.org/10.3390/ijms18061248 |
work_keys_str_mv | AT glubabrzozkaanna personalizedmedicinenewperspectivesforthediagnosisandthetreatmentofrenaldiseases AT franczykbeata personalizedmedicinenewperspectivesforthediagnosisandthetreatmentofrenaldiseases AT olszewskirobert personalizedmedicinenewperspectivesforthediagnosisandthetreatmentofrenaldiseases AT banachmaciej personalizedmedicinenewperspectivesforthediagnosisandthetreatmentofrenaldiseases AT ryszjacek personalizedmedicinenewperspectivesforthediagnosisandthetreatmentofrenaldiseases |